Shark IgNAR-derived binding domains as potential diagnostic and therapeutic agents. (January 2019)

• Record Type: Journal Article
• Authors: Matz, Hanover; Dooley, Helen
• Is Part Of: Developmental and comparative immunology. Volume 90(2019)
• Page Start: 100
• Page End: 107
• Publication Date: 2019-01
• Subjects: Shark -- Antibody -- Immunoglobulin -- IgNAR -- Nanobody; Immunology -- Periodicals; Developmental immunology -- Periodicals; 616.079
• DOI: 10.1016/j.dci.2018.09.007
• Languages: English
• ISSNs: 0145-305X

Abstract

Abstract: Many of the most successful drugs generated in recent years are based upon monoclonal antibodies (mAbs). However, for some therapeutic and diagnostic applications mAbs are far from ideal; for example, while their relatively large size and inherent receptor binding aids their longevity in vivo it can also limit their tissue penetration. Further, their structural complexity makes them expensive to produce and prone to denaturation in non-physiological environments. Thus, researchers have been searching for alternative antigen-binding molecules that can be utilized in situations where mAbs are suboptimal tools. One potential source currently being explored are the shark-derived binding domains known as VNARs. Despite their small size VNARs can bind antigens with high specificity and high affinity. Combined with their propensity to bind epitopes that are inaccessible to conventional mAbs, and their ability to resist denaturation, VNARs are an emerging prospect for use in therapeutic, diagnostic, and biotechnological applications. Highlights: IgNAR is a novel, heavy chain-only antibody isotype found in cartilaginous fishes. VNARs are small, single-domain binding proteins derived from IgNAR. Despite their small size VNARs can bind antigens with high specificity and high affinity. VNARs can bind epitopes inaccessible to conventional mAbs and are resistant to denaturation. VNARs are an emerging prospect for therapeutic, diagnostic, and biotechnological applications.